BioPartnering Europe 2004 Exhibitor Profiles.

LONDON -- BioPartnering Europe 2004 takes place Oct. 10-12, 2004, at the QEII Conference Centre in London. For in-depth information about the event visit http://www.techvision.com/bpe/.

Below are profiles from BioPartnering Europe 2004 exhibitors; breaking news releases and announcements are available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource.

Company: Amgen
Date of Presentation: Tuesday, October 12, 2004
Time of  Presentation: 8:45 a.m. - 9:45 a.m.
Public Relations Contact:  Amgen Corporate Communications
Phone: [phone]
Web: http://www.amgen.com
Press Area URL: http://www.amgen.com/news/

Amgen Inc. (Nasdaq: AMGN), the world's largest biotechnology
company, applies scientific discovery and innovation to fulfill our
mission to serve patients. Harnessing the powerful tools of cellular
and molecular biology and medicinal chemistry, we seek to discover,
develop, and commercialize novel therapeutics that can extend the
reach of medicine.

Amgen supports research programs in inflammation, metabolic
disease and osteoporosis, oncology, hematology/nephrology and
neurology. With expertise in proteins, small molecules, antibodies and
peptibodies, and nucleic acids, our scientists can develop potential
new therapies using the modality best suited for a specific disease
target. Amgen is also a world leader in the manufacture of human
protein-based therapeutics and is currently expanding manufacturing
capabilities to support clinical development and commercial production
of new product candidates across multiple therapeutic modalities.

Company: Apax Partners
Date of Presentation: Monday 11 October 2004
Time of Presentation: 10:15-11:15
Public Relations Contact: Juliana Wheeler
Investor Relations Contact: Joanna Armandias
Phone: [phone]
E-mail: [e-mail]
Web: http://www.apax.com
Press Area URL: http://www.apax.com/EN/dynamic/press_room.aspx

Apax Partners is one of the world's leading private equity
investment groups, operating across Europe, Israel, the United States
and Japan. With over 30 years of direct investing experience, Apax
Partners' Funds provide long-term equity financing to entrepreneurs to
build and strengthen world-class companies. It pursues a balanced
equity portfolio strategy, investing in companies at all stages of
development from venture stage to buy-out. Some of Apax Partners
Funds' recent venture stage healthcare investments include Aerovance,
Affymax, Astex, Biolipox, Cadent, Dune, Intercell, Ionix, Lorantis,
Microscience, Procognia and Wilex. Recent later stage investments
include Medlock Medical, Zeneus Pharma and Regent Medical.

Company: Arrow Therapeutics Ltd
Date of Presentation: Open House Presentation Booth No. 9 -
Monday 11th October
Time of Presentation: 10am-12:30
Public Relations Contact: Miss Margaret Walsh
Investor Relations Contact: Miss Annie Clayton
Phone: [phone]
E-mail: [e-mail]
Web: http://www.arrowt.co.uk

Arrow Therapeutics is a privately owned pharmaceutical company
focussed on research and development of novel anti-infectives. Founded
in 1998 and based in central London, the company has developed a broad
pipeline of early and late stage projects at various stages between
target identification and clinical development. Our Series B funding
round was completed in March 2004 attracting over $43 million.

75 employees work on compounds against Hepatitis C and Respiratory
Syncytial Virus, in addition to novel antibiotics. Our RSV compound
completed Phase I trials in June 2004 and will shortly enter Phase II.
The Hepatitis C compound entered preclinical development in March 2004
and is expected to enter Phase I in early 2005.

Company: Austrianova Biotechnology
Date of Presentation: October 12th, 2004
Time of  Presentation 11:15 a.m.
Public Relations Contact: [e-mail]
Investor Relations Contact: [e-mail]
Phone: [phone]
E-mail: [e-mail]
Web: http://www.austrianova.com
Press Area URL: http://www.austrianova.com/trial.htm

Austrianova, a Vienna-based bio-tech company with 66 employees, is
a leading global specialist in the research, development and
application of targeted virus-based gene delivery systems. The current
focus is on developing treatments of pancreatic and breast cancers
which significantly outperform conventional therapies.

In summer 2003, Austrianova achieved a breakthrough when NovaCaps,
its cell therapy product for targeted treatment of pancreatic cancer
was designated an "Orphan Drug Medicinal Product" by the EMEA. More
recently Austrianova got go ahead by the EMEA for a pivotal clinical
trial with NovaCaps.

This technology could potentially be extended for many other types
of cancers.

Company: Biolex, Inc
Date of Presentation: Tuesday October 12, 2004
Time of Presentation: 9:45-12:15
Public Relations Contact: John Irick
Phone: [phone]
E-mail: [e-mail]
Web: http://www.biolex.com
Press Area URL:  http://www.biolex.com/media.html

Biolex is a private, venture capital-backed biopharmaceutical
company located in the Research Triangle region of North Carolina.
Biolex is developing recombinant human therapeutic proteins and
monoclonal antibodies that, until now, have been impossible or very
expensive to develop in existing protein expression systems. Biolex
utilizes its patented LEX SystemTM, a complete set of technologies and
capabilities demonstrated to significantly enable faster,
less-expensive development and production of hard-to-make proteins
(such as peptides and cytokines) and antibodies. Biolex is developing
its own pipeline of hard-to-make proteins and monoclonal antibodies,
and is establishing partnerships with a number of top-tier
pharmaceutical and biotechnology companies.

Company: Biolipox AB (publ)
Date of presentation: poster presentation - 12/10
Time of presentation: poster presentation - 1.30pm
Public Relations Contact: Jarl Molin
Investor Relations Contact: Torbjorn Bjerke
Phone: [phone]
E-mail: [e-mail]
Web: www.biolipox.com

Biolipox - a research intensive pharmaceutical company

Leading knowledge of novel pathways in inflammatory disease

--Clear scientific and therapeutic focus on asthma, COPD,
rhinitis, pain and arthritis

--Bases on world-class science from Karolinska Institutet

Portfolio of clinical as well as pre-clinical projects

--Pipeline includes products with proven mechanisms as well as
first-in-class compounds

Pipeline targets large markets with high unmet medical needs

Highly experienced management and organisation

Product commercialisation through collaborations

Product Pipeline:

New anti-allergy drug candidate

Selective PGE2 synthase inhibitor

Eoxin blocker

Dual eoxin/leukotriene blocker

Company: BIOQuebec
Public Relations Contact: Ani Armenian
Phone: [phone] x 207
E-mail: [e-mail]
Web: http://www.bioquebec.com
Press Area URL:
http://www.bioquebec.com/Alcyon.cgi?ACTION=Reference&ID=21&Lang=2

Proudly representing its more than 250 members, BIOQuebec is one
the most important networks for bio-industry and health sciences in
Canada.

BIOQuebec is committed to supporting the growth and vitality of
Quebec's biotechnology companies. In this vein, it reaches out
nationally and internationally to position the Quebec biotechnology
community as a center of scientific development and innovation and
works collaboratively with partner organizations to fuel growth of the
province's biotech industry.

BIOQuebec's membership is strengthened by the diversity of company
size and the range of industry sub-sectors. Its members are active in
the following sectors: Human and animal health, agriculture, bio-food
and environment.

Company:  BioRexis Pharmaceutical Corporation
Date of Presentation:  October 11, 2004
Time of  Presentation:  1430-1700
Public Relations Contact: Frederick Jones
Investor Relations Contact: David King
Phone: [phone]
E-mail: [e-mail]
Web: http://www.biorexis.com

BioRexis utilizes proprietary molecular engineering technology to
create new peptide therapeutics using the normal human serum protein
transferrin as a scaffold. The transferrin fusion constructs can
extend half life, reduce dose amounts, improve efficacy and reduce
side effects. Molecular recognition sequences incorporated into
transferrin can perform like monoclonal antibodies while minimizing
antibody intellectual property issues. The therapeutics are produced
in a yeast system, with reduced complexity and cost compared to
mammalian cell systems. BioRexis plans to develop fusion therapeutics
aimed at proven drug targets in large markets.

Company: BioVisioN AG
Date of Presentation: Tuesday, October 12
Time of Presentation: 1:30-4:00
Public Relations Contact: Peter Eisenschmidt
Investor Relations Contact: Wolfgang Trefzger
Phone: [phone]
E-mail: [e-mail]
Web: http://www.peptidomics.com
Press Area: http://www.biovision-discovery.de/set_all.htm

BioVisioN has developed a concept of the comprehensive profiling
of patterns of peptides, and their structural and functional
identification. The proprietary Peptidomics* technologies and
Differential Peptide Display* opens a new window of opportunity in the
discovery and identification of drug leads, drug targets and
biomarkers for diseases like Metabolic syndrome, Alzheimer's disease
and cancer. BioVisioN provides its services within research
collaborations as well as in fee-for-service arrangements.

Company:  CombinatoRx, Inc.
Date of Presentation:  October 11, 2004
Time of  Presentation:  2:30pm - 5:00pm
Public Relations Contact:  Brendan Smith
Investor Relations Contact:  Marli Giannini
Phone:  Brendan Smith: 617-425-7129; Marli Giannini: 617-425-7018
E-mail:  [e-mail]; [e-mail]
Web:  http://www.combinatorx.com
Press Area URL:
http://www.combinatorx.com/news/news_press_releases.html

CombinatoRx, a privately-held pharmaceutical company, is creating
new combination medicines that attack disease on multiple fronts. The
company has an impressive clinical and preclinical pipeline of novel
agents, including treatments in development for cancer and rheumatoid
arthritis, and has ongoing research in respiratory, metabolic, and
infectious diseases. CombinatoRx invented the industry's first
combination drug discovery platform to generate new medicines, based
upon new insights into disease networks, in a broad range of
therapeutic areas. Founded in 2000, the company has raised $90M in
venture capital and is executing on its business strategy to rapidly
build and commercialize a portfolio of breakthrough products.

Company:   De Facto Communications
Date of Presentation:  Conference Sponsor
Public Relations Contact: Louise Sarup
Phone: [phone]
E-mail: [e-mail]
Web:  http://www.defacto.com

De Facto Communications is a leader in life science and healthcare
communications. Working in partnership with our clients, we approach
our work with passion and a commitment to delivering award-winning
solutions that combine effective strategy with original thinking and
creativity.

As one of Europe's most successful public relations consultancies
working specifically in the healthcare and life science arena, we
offer fully integrated communications programmes for organisations in
these sectors. Our clients, from across Europe and the US, range from
small start-ups to large pharmaceutical companies and from trade
associations to Government initiatives. Services we offer include PR,
Marketing, Writing, Design and New Media.

Company: Drug Royalty Corporation Inc.
Investor Relations Contact: Ali Alagheband
Phone: [phone] ext. 227
E-mail: [e-mail]
Web: http://www.drugroyalty.com

Drug Royalty offers innovative sources of financing to inventors,
institutions and life sciences companies who develop pharmaceutical
products, diagnostics or medical devices. With a pool of more than
$200 million in available investment capital over the next two years,
Drug Royalty invests in carefully selected products already on the
market or in late-stage clinical development. Our royalty financing
model is two-fold:

--We acquire existing royalty streams.

--We create new royalty streams by providing funds in return for a
percentage of product revenues.

Drug Royalty has cultivated partnerships with stakeholders in some
of today's leading products, including Neupogen, Remicade, Taxol,
Clarinex, Thalomid, and Abreva. Drug Royalty works closely with
clients to structure unique transactions and negotiate agreements that
are fair for both parties. Drug Royalty will purchase all or part of a
royalty entitlement and can structure transactions to include upside
participation, adding greater assurance that customers will continue
to benefit from the future performance of their royalties.

Drug Royalty was founded in 1992 and is the originator of royalty
based financing for the life sciences industry. Drug Royalty is a
wholly owned subsidiary of Inwest Investments Ltd., a preeminent
private Canadian investment management firm. To date, the company has
acquired more than $140 million of royalty interests from industry,
research institutions and inventors.


Company: EGeen International Corporation
Date of Presentation: October 11th, 2004
Time of  Presentation: 10:00 am - 12:30 pm
Public Relations Contact: Kalev Kask
Phone: [phone]
E-mail: [e-mail]
Web: http://www.egeeninc.com

EGeen's business focus is to conduct drug development via
expeditious and cost-effective clinical trials in all major disease
areas. The key assets of EGeen include proprietary clinical databases
to identify trial participants, an extensive network of highly
qualified medical doctors for rapid patient enrollment, and a highly
cost-effective infrastructure.

EGeen currently conducts clinical trials under affordable
fee-for-service arrangements. EGeen is also engaged in several
co-sharing arrangements where EGeen conducts clinical trials with no
or reduced resource requirement from the partners in exchange for
downstream participation of sales. EGeen will engage in clinical
development of its proprietary compounds acquired through
in-licensing.

Company:  Health Protection Agency
Date of Presentaion:  Monday 11th October
Time of Presentation:  Open House Presentation, Monday afternoon
Public Realtions Contact:  Phil Luton; 01980 612725 or 07887 656001;
[e-mail]
Investor Relations Contact:  David Rhodes; 01980 612221;
[e-mail]
Phone:  [phone]
E-mail:  [e-mail]
Web:  http://www.hpa.org.uk

The Health Protection Agency (HPA) is a national organisation
which is dedicated to protecting people's health and reducing the
impact of infectious diseases, chemical hazards, poisons and radiation
hazards.

The Business Division of the HPA is based at Porton Down, formally
CAMR. HPA Porton Down's core business areas are research and
development of vaccines against infectious diseases, process
development and GMP manufacture of biologics derived from microbial
fermentation - particularly those requiring containment or focused on
the bio-defence market. In addition, a wide range of support services
are offered from biosafety, through GLP immunoassay testing to in-vivo
studies and the supply of cell cultures.

Company: Ingenium Pharmaceuticals AG
Date of Presentation: October 11, 2004
Public relations and Investor relations contact:
Gretchen L. P. Schweitzer
Phone: [phone]
E-mail: [e-mail]
Web:  http://www.ingenium-ag.com

Ingenium Pharmaceuticals is a drug discovery company that bases
its business on generating the biological information critical to the
discovery and development of therapeutics. From the knowledge
generated by its Deductive Genomics(R) technology, Ingenium is
advancing a portfolio of drug targets and has a major collaboration
with Elan Corporation in the area of pain management. The company's
INGENOtyping(R) platform offers the most rapid access to genetic mouse
and rat models. Ingenium has multiple partnership agreements with
biopharmaceutical companies across the industry, including such
companies as Elan, Bayer AG, F. Hoffmann-La Roche Ltd., and Wyeth in
addition to numerous academic collaborations.

Company:  Jerini AG
Public Relations Contact:  Helena Dreznjak; + 49 - 30 - 97893 - 118;
[e-mail]
Web:  http://www.jerini.com

Jerini AG is a drug discovery and development company based in
Berlin, Germany. The company discovers and develops drugs with a
peptide technology platform. Jerini's lead product Icatibant is
currently in pivotal registration studies in the indication hereditary
angioedema. The company aims for first market approval in 2006/2007.
Jerini will develop Icatibant in further indications and has several
compounds in the preclinical stages for different diseases. The
company is supported by an international consortium of investors and
has raised over EUR 55 million since 2000. Jerini's long term goal is
to become a globally acting fully integrated pharma company.

Company: Lectus Therapeutics Limited
Date of Presentation: 11th October 2004
Time of Presentation: 3.15pm
Public Relations Contact: Roland Kozlowski
Phone: [phone]
Email: [e-mail]
Web: http://www.lectustherapeutics.com/
Press Area URL: http://www.lectustherapeutics.com/News.html

Lectus Therapeutics Limited is an emerging UK-based
bio-pharmaceutical company, which specialises in the discovery and
development of drugs for diseases associated with smooth muscle
hyperreactivity, such as urinary bladder disorders, angina and
hypertension.

Lectus Therapeutics is utilising its proprietary functional
proteomics platform, LEPTICSTM (Leveraged Enabling Proteomics
Technology for Ion Channel Screening), and building on its knowledge
of ion channels and protein-protein interactions, to develop
next-generation ion channel modulators that offer important clinical
and economic advantages over existing therapies.

Company: MedPharm Ltd
Date of Presentation: Tuesday, 12th of October
Time of  Presentation: 9:30am - Open-House Presentation
Public Relations Contact: Carole Delauney
Investor Relations Contact: Andrew Muddle
Phone: [phone]
E-mail: [e-mail]
Web: http://www.medpharm.co.uk
Press Area URL: http://www.medpharm.co.uk/n_news.html

MedPharm Ltd is a pharmaceutical formulation development company
committed to the creation of unique therapeutic systems for dermal,
mucosal, nasal and pulmonary drug delivery.

MedPharm offers a highly specialised service in the area of
pharmaceutical contract research and development. Services include
analytical, formulation, in vitro and performance testing, ranging
from feasibility studies to production of GMP clinical supplies for
Phase I/II trials and technology transfer to manufacturing sites.

In parallel to its projects for clients, MedPharm is actively
working to create its own pipeline of transdermal, topical and
pulmonary drug delivery technologies.

The team combines years of commercial experience in the
pharmaceutical industry with the benefit of high-calibre scientists
and has access to the significant technical and intellectual resources
of King's College London's Department of Pharmacy (UK).

Company: MorphoSys AG
Date of Presentation: Monday, October 11th 2004
Time of Presentation: 10.00 - 12.30
Public Relations Contact: Mario Brkulj
Investor Relations Contact: Claudia Gutjahr-Loser
Phone: [phone]
E-mail: [e-mail]
Web: http://www.morphosys.com

MorphoSys is a biotechnology company which develops and applies
innovative technologies in order to discover disease related targets
and new drugs. The Company's technologies emphasize the use of fully
human antibodies in both research and therapeutic applications.
Foremost among these technologies is HuCAL(R), the Human Combinatorial
Antibody Library, a collection of more than 12 billion distinct fully
human antibodies. Importantly, HuCAL(R) antibody libraries possess the
unique capability of enabling optimization of fully human antibodies -
an essential differentiating feature compared to other human antibody
generation technologies, and one which is of significant value.

Company: Morphotek Inc.
Date of Presentation: October 12, 2004
Time of  Presentation: 9:45 am-12:15pm
Public Relations Contact: Philip M. Sass
Investor Relations Contact: Nicholas C. Nicolaides
Phone:  [phone]
E-mail: [e-mail]
Web: http://www.morphotek.com

Morphotek(R) Inc. is a biotechnology company specializing in the
development of protein and antibody products through the use of a
novel and proprietary gene evolution technology. The technology has
been successfully applied to a broad variety of cell lines and
organisms to yield genetically diverse offspring that are suitable for
pharmaceutical product development in the areas of antibody
therapeutics, protein therapeutics, product manufacturing, drug target
discovery, and improved output traits for commercial applications. The
company is currently focusing its platform on the development and
manufacturing of therapeutic antibodies for the treatment of cancer,
inflammation and infectious disease.

Company: Mosaic Systems BV
Date of Presentation: October 11th, 2004
Time of Presentation: 15:00 - 15:15 hr
Public Relations Contact: Erik van Wijk
Phone: [phone]
E-mail: [e-mail]
Web: http://www.mosaicsystems.nl
Press Area URL: http://www.mosaicsystems.nl/news.php

Mosaic Systems BV is a dutch biotech-focussed company specializing
in large scale biologics separation and purification for
(Bio)Pharmaceuticals, Food Ingredients and Dairy/Agri.

Mosaic Systems BV develops technology that speeds up bioprocessing
in process development and final manufacturing providing a 4 to more
than 50 times higher productivity, resulting in significantly lower
operational costs.

We develop Mosaic Systems ModuleTM concepts to perform under a
wide variety of process conditions, for high productivity, high
resolution and low buffer consumption based on your current
chromatography medium.

Company: Neuro3d
Date of Presentation: 12.10.2004
Time of  Presentation: 9:30 to 12:00
Public Relations Contact: Lubor Gaal
Investor Relations Contact: Charles Woler
Phone: [phone]
E-mail: [e-mail]
Web: http://www.neuro3d.fr

Neuro3d S.A. is a biopharmaceutical company focusing on the
discovery and development of innovative treatments for psychiatric
disorders specifically, schizophrenia, depression and anxiety.

Neuro3d currently develops two clinical drugs and a third drug to
enter clinical studies soon. The atypical antipsychotic ocaperidone is
in Phase II for Schizophrenia. ND1251 is a PDE-4 inhibitor in Phase I
for depression and ND7001 is a new type of antidepressant with
anxiolytic activity that will start Phase I in Q4 2004. The research
programs focus on new treatment concepts (1st in class) and have lead
to the identification of new types of compounds acting via new
mechanisms of actions.

Company: OctoPlus
Date of Presentation: Monday October 11th
Time of Presentation: 10 - 12.30 hrs
Public Relations Contact: Gerben Moolhuizen
Investor Relations Contact: Henrik Luessen
Phone: [phone]
E-mail: [e-mail]
Web: http://www.octoplus.nl
Press Area URL: http://www.octoplus.nl/news/index.asp

OctoPlus is an established provider of pharmaceutical development
services and cGMP manufacturing of final product to pharmaceutical and
biotechnology companies world-wide. Our strong expertise is in the
formulation of biotech-derived therapeutics and low soluble compounds
for oral, parenteral, topical and pulmonary administration.

OctoPlus also develops PolyActiveTM and OctoDExTM: two proprietary
biodegradable drug delivery platforms for proteins, peptides, DNA, and
small molecules. We use these drug delivery platforms to develop
sustained release formulations for our partners and to build our own
product pipeline.

The company was established in 1995 and employs approximately 100
people. OctoPlus is located in Leiden, The Netherlands.

Company: R.J. Watkins & Company, Ltd.
Phone: [phone]
E-mail: [e-mail]
Web: http://www.rjwatkins.com

People. Technology. Capital. These three elements are an essential
combination to create market value for a company. Since its founding
in 1980, R.J. Watkins & Company, Ltd. has assisted a wealth of leading
edge companies by creating value through high-impact candidate
selection.

R.J. Watkins & Company, Ltd. specializes in addressing the
leadership needs of life science- and technology-based firms on a
global basis, from start-up ventures to multi-national corporations.

With offices in San Diego, San Francisco, Hong Kong and London,
R.J. Watkins & Company, Ltd. celebrates 25 years of success in
identifying quality leadership.

Company: Roche
Date of Presentation: October 11th 2004
Time of  Presentation: 0845
Public Relations Contact: Judith Moloney
Investor Relations Contact: Eva-Maria Schaffer
Phone: [phone]
E-mail: [e-mail]
Web: http://www.roche.com

Roche is one of the world's premier innovation-driven healthcare
groups, focused on pharmaceuticals and diagnostics. Roche is a leader
in the global diagnostics market, a main supplier of pharmaceuticals
for cancer and a leader in virology and transplantation. Roche employs
around 65,000 people in 150 countries. The Group has more than 50
active alliances with biotechnology companies worldwide and owns
majority interests in Genentech and Chugai.

Roche's key areas of interest are: oncology and hematology;
transplantation; virology; central nervous system; metabolic;
cardiovascular; respiratory; inflammatory, genitourinary; and
preclinical research and technologies. With a commitment to true
collaboration, Roche has an experienced global team, dedicated to
forming mutually beneficial alliances.

Company:  Santhera Pharmaceuticals
Date of Presentation:  10-12 October, 2004
Public Relations Contact:  Natascha Blank; [phone];
[e-mail]
Investor Relations Contact:  Helmut Kessmann; [phone];
[e-mail]
Web:  http://www.santhera.com

Privately held Santhera Pharmaceuticals AG, headquartered in
Switzerland, has operations in Liestal, Switzerland (near Basel), and
in Heidelberg Germany, as well as a business development office in
Boston, MA, USA. It is a drug discovery and development business which
was formed in August 2004 through the merger of MyoContract AG and
Graffinity Pharmaceuticals AG. The company is focused on the
discovery, preclinical and clinical development, and commercialization
of pharmaceuticals for neuromuscular and metabolic diseases. Through
its Graffinity Technology division, Santhera offers access to its
proprietary small molecule drug fragment micro-array screening
platform

Company: Serologicals Corporation
Public Relations Contact: Bill Davis
Investor Relations Contact: Craig Brown
Phone: [phone]
E-mail: [e-mail]
Web: http://www.serologicals.com

Serologicals Corporation is a global provider of biological
products and enabling technologies, which are essential for the
research, development and manufacturing of biologically based life
science products.

Our products and technologies are used in a wide variety of
innovative applications within the areas of oncology, hematology,
immunology, cardiology and infectious diseases, as well as in the
study of molecular biology.

Serologicals Corporation, headquartered in Atlanta, Georgia, has
more than 750 employees worldwide, and its shares are traded on the
NASDAQ national stock market under the symbol SERO.

Company: Sidec Technologies AB
Date of Presentation: Tuesday October 12th,
Time of Presentation: 9:45-12:15
Public Relations contact: Malin Engstrom, [e-mail]
Investor Relations Contact: Hans Johansson, [e-mail]
Phone: [phone]
E-mail: info.sidec.com
Web: http://www.sidec.com
Press Area URL: http://www.sidec.com/index5.html

Sidec Technologies is a privately held company, spun out of
research from the Karolinska Institute in Sweden. The company has
developed a proprietary technology, Sidec(TM) Electron Tomography
(SET), to study cellular or soluble proteins such as GPCR and
ion-channels or interacting proteins from tissue, cell systems or in
buffer solutions. Through the structure - function research unit in
Stockholm, Sidec is offering the drug discovery and biopharmaceutical
industry access to the technology. We deliver result in the form of
3-D images and numerical data based on statistical analysis. Sidec is
the first and only commercial company offering structure - function
related discovery based on high resolution electron microscopy.

Company: TargeGen, Inc.
Date of Presentation: October 12, 2004
Time of  Presentation: 1:30 PM
Public Relations Contact: Sue Gordon ([e-mail])
Investor Relations Contact: Wood Erwin VP Finance ([e-mail])
Phone: [phone]
E-mail: [e-mail]
Web: http://www.targegen.com

TargeGen is a vascular biology focused company that is developing
small molecule drugs (kinase inhibitors) which inhibit vascular
permeability, vascular proliferation, or both. The company targets
diseases where edema or neovascularization are major contributors to
tissue damage or mortality. Edema is an area of great unmet need and
contributes to tissue death and morbidity across some 15 major
diseases including heart attack, cancer, stroke, eye disease,
pulmonary edema, pleural effusions, transplant ischemia, and other
disorders. Current therapies are primarily limited to steroids and
drainage. The company currently has three drug candidates in
development:

1)       TG100-115 - Phase I/II (Acute Myocardial Infarction)
2)       TG100-344 - Late pre-clinical (Cancer)
3)       TG100-344 - Early pre-clinical (Macular Degeneration - AMD)

The company is actively seeking licensing or joint development
partners.


Company: TopoTarget A/S
Date of Presentation: Tuesday 12th October
Time of Presentation: 9:45- 12:15, Booth 6
Public Relations Contact: Nicki Brimicombe; + 44 (0) 1883 732353
Investor Relations Contact: Tim Corcoran; [phone]
E-mail: [e-mail]
Web: http://www.topotarget.com

TopoTarget A/S is a biopharmaceutical company focused on the
development of novel pharmaceutical compounds and finding new uses for
existing drugs in the treatment of cancer and cancer-related
indications. The Company was established in 2000 by clinical
oncologists. As such, it has extensive clinical experience and a deep
understanding of the molecular mechanisms of cancer, particularly DNA
damage control, chromatin control and cell-cycle control. TopoTarget
uses predictive clinical models to refine the efficacy of potential
drugs against cancer cells exhibiting different resistance properties.
The Company has four product candidates in clinical development and
six projects in pre-clinical research.

Company: U3 Pharma AG
Date of Presentation: Tuesday, October 12
Time of Presentation 2:15 - 2:30 p.m.
Public Relations Contact: Edward Stuart
Phone: [phone]
E-mail: [e-mail]
Web: http://www.u3pharma.com

U3 Pharma is a biopharmaceutical company focusing on the
development of novel anti-cancer therapeutics that address diseases
with significant medical need and commercial importance. U3 Pharma is
creating the next generation of targeted therapeutics that inhibit
novel signal transduction mechanisms that act as key drivers of
malignancy. Founded by Axel Ullrich in 2001, U3 Pharma currently
employs 25 people and is based in Martinsried, Germany. Through two
rounds of financing, U3 Pharma has attracted the support of leading
international and US-based VC funds including Alta Partners, LCF
Rothschild Venture Partners and Atlas Venture.